Sage Journals: Discover world-class research

Abstract

Keywords

immune checkpoint blockers tumor response BCC SCC tumor infiltrating lymphocytes

Get full access to this article

View all access options for this article.

References

Emens

LA.

Butterfield

LH.

Hodi

FS.

Marincola

FM.

Kaufman

. Cancer immunotherapy trials: leading a paradigm shift in drug development. J Immunother Cancer. 2016;4:42.doi:10.1186/s40425-016-0146-9

Sabbatino

Marra

Liguori

et al. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature. J Immunother Cancer. 2018;6(1):126.doi:10.1186/s40425-018-0439-2

Migden

MR.

Rischin

Schmults

et al. PD-1 blockade with Cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341-351.doi:10.1056/NEJMoa1805131

Yost

KE.

Satpathy

AT.

Wells

et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019;25(8):1251-1259.doi:10.1038/s41591-019-0522-3

Duhen

Montler

et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018;9(1):2724.doi:10.1038/s41467-018-05072-0

Cytotoxic T Cells Are Replaced by Novel Clones After Immune Checkpoint Blocker Therapy

Abstract

Keywords

Get full access to this article

References